Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity.

Taylor J MoonHieu Minh TaAnubhuti BhalotiaKai E PaulsenDiarmuid W HutchinsonGabrielle M ArkemaAndrew S ChoiMichiko G HaynieLaolu OgunnaikeMargee DeverLi Lily WangEfstathios Karathanasis

Published in: Journal for immunotherapy of cancer (2024)

Our studies show the dual-LNP ensured codelivery of its synergistic cargoes to tumor-infiltrating myeloid cells, leading to simultaneous silencing of VISTA and stimulation of TLR9. As a result, the dual-LNP drove a highly potent antitumor immune response that rejected large aggressive tumors, thus may be a promising therapeutic platform for treating immune-cold tumors.

Keyphrases

immune response
induced apoptosis
dendritic cells
toll like receptor
cancer therapy
cell cycle arrest
anti inflammatory
inflammatory response
acute myeloid leukemia
high throughput
cell death
signaling pathway
protein protein
drug delivery
case control
small molecule
nuclear factor
pi k akt